Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · Real-Time Price · USD
3.260
+0.070 (2.19%)
At close: Aug 29, 2025, 4:00 PM
3.320
+0.060 (1.84%)
After-hours: Aug 29, 2025, 7:56 PM EDT
Applied DNA Sciences Revenue
Applied DNA Sciences had revenue of $304.39K in the quarter ending June 30, 2025, a decrease of -35.62%. This brings the company's revenue in the last twelve months to $3.74M, up 55.60% year-over-year. In the fiscal year ending September 30, 2024, Applied DNA Sciences had annual revenue of $3.43M, down -74.33%.
Revenue (ttm)
$3.74M
Revenue Growth
+55.60%
P/S Ratio
0.17
Revenue / Employee
$77,980
Employees
48
Market Cap
4.21M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.43M | -9.94M | -74.33% |
Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
APDN News
- 17 days ago - Applied DNA Reports Third Quarter Fiscal 2025 Financial Results - Accesswire
- 5 weeks ago - Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application - Accesswire
- 7 weeks ago - Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements - Accesswire
- 2 months ago - Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx - Accesswire
- 2 months ago - Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward - Accesswire
- 2 months ago - Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August - Accesswire
- 3 months ago - Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 - Accesswire
- 3 months ago - Applied DNA Reports Second Quarter Fiscal 2025 Financial Results - Accesswire